Physician profile
Stephanie E Gort
NPI 1043610462
$18,849.37
in general payments reported to CMS, 2019-2025
26 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $563 · 2023: $866 · 2024: $1,432 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $5,183 · Travel and Lodging: $1,349 · Consulting Fee: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,415.25 |
| Food and Beverage | $5,182.92 |
| Travel and Lodging | $1,348.68 |
| Consulting Fee | $1,215.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11,922.38 | 2022-2025 | Wegovy |
| Madrigal Pharmaceuticals | $2,582.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $897.78 | 2022-2025 | |
| Ardelyx, INC. | $606.60 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $498.25 | 2021-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $416.01 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.13 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $234.41 | 2024-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $205.66 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $165.03 | 2023-2025 | Linzess |
| Celgene Corporation | $156.62 | 2022-2024 | Zeposia |
| Medtronic, INC. | $123.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.42 | 2022 | |
| Pfizer INC. | $99.86 | 2023-2025 | |
| Celltrion USA INC. | $91.51 | 2025 | Vegzelma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $79.70 | 2021-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $71.64 | 2023 | |
| Qol Medical, LLC | $65.95 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $61.85 | 2023-2024 | Ocaliva |
| Braintree Laboratories, INC. | $37.81 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $32.34 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $23.17 | 2024 | Idacio |
| Exact Sciences Corporation | $22.69 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $20.01 | 2025 | |
| Blueprint Medicines Corporation | $16.38 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.41 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Gort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.